Krystal Biotech Inc (KRYS)
Liquidity ratios
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 12.66 | 17.76 | 21.10 | 20.25 | 10.13 | 13.30 | 14.18 | 12.45 | 7.25 | 17.18 | 9.67 | 20.42 | 44.38 | 17.80 | 39.96 | 51.20 | 46.38 | 58.88 | 54.87 | 49.80 |
| Quick ratio | 12.29 | 17.35 | 20.72 | 19.98 | 9.99 | 13.15 | 14.07 | 12.36 | 7.19 | 17.02 | 9.59 | 20.29 | 44.12 | 17.56 | 39.79 | 50.97 | 45.97 | 58.22 | 54.54 | 49.62 |
| Cash ratio | 11.31 | 16.08 | 20.38 | 19.98 | 9.99 | 13.15 | 14.07 | 12.36 | 7.19 | 17.02 | 9.59 | 20.29 | 44.12 | 17.56 | 39.79 | 50.97 | 45.97 | 58.22 | 54.54 | 49.62 |
Krystal Biotech Inc's liquidity ratios, including the current ratio, quick ratio, and cash ratio, have exhibited fluctuations over the past few quarters. The current ratio, a measure of the company's ability to cover its short-term obligations with its current assets, has been significantly high, ranging from 7.25 to 58.88, with a notable spike in the December 2022 quarter.
Similarly, the quick ratio, which focuses on more liquid assets to cover short-term liabilities, also displayed a similar trend, ranging from 7.19 to 58.22. The cash ratio, providing an even stricter assessment of immediate liquidity, mirrored this behavior, varying between 7.19 and 58.22.
Overall, Krystal Biotech Inc appears to maintain a strong liquidity position, with ample current assets to cover its short-term obligations. However, the company experienced some fluctuations in its liquidity ratios, suggesting potential shifts in its asset composition or operating efficiency over the quarters. Further analysis would be needed to understand the drivers behind these fluctuations and their implications for the company's financial health.
Additional liquidity measure
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 187.09 | 282.02 | 366.68 | -13.33 | -17.94 | -19.17 | -32.05 | -60.98 | -63.51 | -78.72 | -55.22 | -17.45 | -33.70 | -55.96 | -77.69 | -65.05 | -31.33 | -57.43 | -79.95 | -63.10 |
The cash conversion cycle of Krystal Biotech Inc has shown fluctuations over the past few quarters. The trend indicates that the company's efficiency in managing its working capital has varied significantly.
In the most recent quarter, ending March 31, 2024, the cash conversion cycle was 187.09 days, implying that it takes the company approximately 187 days to convert its investments in raw materials into cash from sales. This represents an improvement compared to the previous quarter, where the cycle was 282.02 days.
The negative cash conversion cycle recorded in June 30, 2023, and March 31, 2023, suggests that in those quarters, the company was able to convert its inventory into cash before paying its suppliers, leading to a favorable working capital position.
However, the substantial positive cycles observed in prior periods, such as December 31, 2023, and September 30, 2023, indicate that the company may have faced challenges in managing its inventory, accounts receivable, and accounts payable efficiently, resulting in cash being tied up in the operational cycle for an extended period.
Overall, the cash conversion cycle trend for Krystal Biotech Inc indicates fluctuations in the company's working capital management effectiveness. Periods of negative cycles signify efficient working capital utilization, while positive cycles suggest possible inefficiencies in the company's operations or challenges in managing its liquidity effectively.